Molecular basis of potassium channels in pancreatic duct epithelial cells

Mikio Hayashi[†,*] and Ivana Novak*

Department of Biology; University of Copenhagen; Copenhagen, Denmark;
[†]Current affiliation: Department of Physiology; Kansai Medical University; Hirakata, Japan

Potassium channels regulate excitability, epithelial ion transport, proliferation, and apoptosis. In pancreatic ducts, K^+ channels hyperpolarize the membrane potential and provide the driving force for anion secretion. This review focuses on the molecular candidates of functional K^+ channels in pancreatic duct cells, including *KCNN4* (K_{Ca}3.1), *KCNMA1* (K_{Ca}1.1), *KCNQ1* (K_v7.1), *KCNH2* (K_v11.1), *KCNH5* (K_v10.2), *KCNT1* (K_{Ca}4.1), *KCNT2* (K_{Ca}4.2), and *KCNK5* (K_{2P}5.1). We will give an overview of K^+ channels with respect to their electrophysiological and pharmacological characteristics and regulation, which we know from other cell types, preferably in epithelia, and, where known, their identification and functions in pancreatic ducts and in adenocarcinoma cells. We conclude by pointing out some outstanding questions and future directions in pancreatic K^+ channel research with respect to the physiology of secretion and pancreatic pathologies, including pancreatitis, cystic fibrosis, and cancer, in which the dysregulation or altered expression of K^+ channels may be of importance.

Introduction

Potassium channels (K^+ channels) are very important membrane proteins present in every cell. They determine the cell membrane

*Correspondence to: Mikio Hayashi; Email: hayashmi@hirakata.kmu.ac.jp; Ivana Novak; Email: inovak@bio.ku.dk

potential and thereby regulate the excitability of neurons and myocytes and transport of ions and water in epithelia, such as the pancreas and salivary glands. Duct epithelial cells in the pancreas secrete a HCO_3^--rich pancreatic juice that neutralizes acid chyme in the duodenum. Secretin, acetylcholine, and ATP stimulate fluid secretion via signal transduction involving cAMP and Ca^{2+} signaling pathways. The generally accepted model for HCO_3^- transport involves Cl^-–HCO_3^- exchangers (SLC26A3 and SLC26A6) that operate in parallel with cAMP-activated Cl^- channels (CFTR) or Ca^{2+}-activated Cl^- channels (most likely TMEM16A) on the luminal membrane and Na^+-coupled transporters such Na^+–K^+–Cl^- co-transporter (NKCC1), Na^+–HCO_3^- co-transporter (SLC4A4), and Na^+–H^+ exchanger (SLC9A1) and Na^+–K^+-pump on the basolateral membrane (**Fig. 1**).[1-3] In addition, H^+–K^+-pumps are expressed on the luminal and basolateral membranes of pancreatic ducts.[4] K^+ channels are clearly important for setting the resting membrane potential and providing the driving force for anion exit and fluid secretion in a stimulated epithelium.[1-3,5] K^+ channels may also provide the transport partners for H^+–K^+-pumps.[4] In addition, certain K^+ channels could play an important role in pancreatic pathology, such as cystic fibrosis, pancreatitis, and pancreatic adenocarcinoma. Perhaps surprisingly, there are not so many K^+ channels studies performed on pancreatic ducts.

Early electrophysiological studies using microelectrodes and patch-clamp methods indicated that pancreatic ducts expressed voltage- and Ca^{2+}-activated K^+-channels, consistent with maxi-K^+ channels (BK channels), intermediate-conductance Ca^{2+}-activated

Figure 1. Model of ion transport in a pancreatic duct cell. Intracellular HCO_3^- is derived from CO_2 through the action of carbonic anhydrase (CA) and from HCO_3^- uptake via the Na^+–HCO_3^- cotransporter. H^+ is extruded at the basolateral membrane by the Na^+–H^+ exchanger and H^+–K^+ pump. HCO_3^- efflux across the luminal membrane is mediated by Cl^-–HCO_3^- exchangers and/or Cl^- channels, and the H^+–K^+ pump may provide a buffering/protection zone for the alkali-secreting epithelium. K^+ channels provide an exit pathway for K^+ and play a vital role in maintaining the membrane potential, which is a crucial component of the driving force for anion secretion.

K^+ channels (IK channels), and pH/HCO_3^- sensitive K^+ channels.[6-13] Recent studies focusing on molecular candidates have shown that pancreatic ducts express the following channels that could be candidates for above functional channels: $K_{Ca}1.1$ channels coded by the *KCNMA1* and *KCNMB1* genes (α – and β-subunits of the BK channel); the $K_{Ca}3.1$ protein coded by the *KCNN4* gene (IK channel); the *KCNK5* gene ($K_{2P}5.1$); and they also express: *KCNQ1* ($K_v7.1$, KVLQT1), *KCNH2* ($K_v11.1$, HERG), *KCNH5* ($K_v10.2$, EAG2), *KCNT1* ($K_{Ca}4.1$, Slack), and *KCNT2* ($K_{Ca}4.2$, Slick), the functions of which remain unclear in duct cells.[10,11,13]

It is not known whether many of these candidates are functional in pancreatic ducts or what is their localization and regulation. Therefore, their physiological and possibly pathophysiological functions have not to be confirmed. The aim of this review is to provide an overview of the above mentioned K^+ channels with respect to their electrophysiological and pharmacological characteristics and functions, as we know from other cell types, preferably in epithelia, and, where known, their identification and functions in pancreatic ducts is given (**Table 1**). We also address some outstanding questions and future directions in pancreatic K^+ channel research.

KCNN4 ($K_{Ca}3.1$, IK, SK4)

Tissue expression

KCNN4 coding for the $K_{Ca}3.1$ protein was cloned from the placenta and pancreas.[14,15] Functional expression of the *KCNN4*

gene has been demonstrated in colonic crypts,[16] salivary acini,[17-19] and pancreatic ducts.[11,13] Immunoreactivity of the $K_{Ca}3.1$ protein has also been reported in the esophagus, stomach, small intestine, proximal colonic crypts, salivary glands, luminal membrane of lacrimal gland duct cells,[20-22] and intercalated and intralobular ducts of the pancreas.[13,23] Interestingly, $K_{Ca}3.1$ channel immunoreactivity was shown to be localized in both the basolateral and luminal membranes in pancreatic ducts and monolayer of Capan-1, a human pancreas adenocarcinoma cell line, though its expression appeared to be stronger in the luminal membrane. Consistent with this finding, the short-circuit current (I_{sc}) of the Capan-1 cell monolayer was enhanced by the $K_{Ca}3.1$ channel activator DC-EBIO in luminal or basolateral bathing solution.[13,24] $K_{Ca}3.1$ could potentially be an important candidate for luminal K^+ channels in pancreatic ducts. Importantly, equivalent-circuit analysis revealed that luminal K^+ conductance contributed to a minimum of 10% of the total K^+ conductance in pancreatic duct cells.[8] Moreover, stimulation of the rat pancreas with secretin caused a marked increase in K^+ concentrations in the pancreatic juice, which was equal to twice that in the plasma, indicating that K^+ was secreted.[25] K^+ efflux was also shown to be mediated via mucosal $K_{Ca}3.1$ channels in other epithelia, such as the distal colon, and provided, in part, the driving force for agonist-induced anion secretion.[26] Another example is salivary acini, in which both $K_{Ca}1.1$ and $K_{Ca}3.1$ were shown to be expressed on the apical membrane and contribute to optimal secretion.[27] Furthermore, H^+–K^+-pumps were reported to be expressed on the luminal membranes of pancreatic ducts[4] and their function, such as contributing to local epithelial protection, appeared to depend on the operation of K^+ channels.

Channel properties

Patch-clamp studies using *Xenopus* oocytes and mammalian expression systems established the basic electrophysiological and pharmacological properties of $K_{Ca}3.1$ channels.[15,28,29] Single-channel openings were observed at both positive and negative membrane potentials, and this gating showed no significant voltage dependency. The single-channel current–voltage relationship showed weak inward rectification with conductance of 30–54 pS in heterologous expression systems. Interestingly, intermediate-conductance K^+ channels exhibited a conductance of 80 pS in rat pancreatic duct cells.[13] One explanation for this discrepancy is that unidentified auxiliary proteins for $K_{Ca}3.1$ channels or additional *KCNN4* genes may exist in rodent cells. Regarding pharmacology, $K_{Ca}3.1$ currents were inhibited by charybdotoxin, clotrimazole, TRAM-34, and maurotoxin with K_i values of 2–28 nM, 25–150 nM, 20 nM, and 1 nM, respectively.[15,28-32] $K_{Ca}3.1$ currents were also activated by 1-EBIO and DC-EBIO with K_d values of 15–84 μM and 0.8 μM, respectively.[28,29,31,33]

Regulation

Regarding regulation, it is well established that $K_{Ca}3.1$ channels are activated by the Ca^{2+}/calmodulin signaling pathway. For example, heterologously expressed $K_{Ca}3.1$ channels were previously shown to be activated by submicromolar free Ca^{2+} concentrations with EC_{50} values of 0.1–0.3 μM.[14,15,29,31] There is also strong evidence to suggest that the Ca^{2+} sensitivity of $K_{Ca}3.1$ channels is mediated by calmodulin and calmodulin

Table 1. Molecular candidates of functional K^+ channels in pancreatic duct cells

Gene	Protein	Conductance (p)S	Blockers (K_i)	Activators (K_d)	Regulation
KCNN4	$K_{Ca}3.1$	30–54[15,28,29]	charybdotoxin (2–28 nM)[15,28,29,31] clotrimazole (25–150 nM)[15,28-31] TRAM-34 (20 nM)[30] maurotoxin (1 nM)[32]	1-EBIO (15–84 μM)[28,29,31,33] DC-EBIO (0.8 μM)[33]	Ca^{2+} [14,15,29,31] calmodulin[18,29,34] PKA[19,42,43] extracellular UTP[11] cell swelling[47,48]
KCMA1	$K_{Ca}1.1$	100–270[50,56]	tetraethylammonium (0.14 mM)[50] charybdotoxin (1–31 nM)[57,58,62] iberiotoxin (1–9 nM)[58,61,62] paxilline (2–9 nM)[58-60]	NS1608 (2 μM)[60] NS11021 (0.4 μM)[63]	membrane potential[7,50,56,64] Ca^{2+} [7,50,56,64] PKA[7,56] extracellular UTP[11]
KCNQ1	$K_v7.1$	0.7–4[80,81]	chromanol 293B (10–41 μM)[68,82,86,87] azimilide (77 μM)[86] XE991 (0.8 μM)[88]	L-364,373[90]	membrane potential[78-81] cAMP[91] cytosolic pH[83]
KCNQ1/ KCNE1	$K_v7.1$/ minK	4.5–16[80,81]	chromanol 293B (3–10 μM)[70,82,86,87] azimilide (5.6 μM)[86] XE991 (11 μM)[88] Mefloquine (0.9 μM)[89]	DIDS[86] mefenamic acid[86]	membrane potential[78-81] cAMP[91,92] cytosolic pH[83]
KCNH2	$K_v11.1$	10–13[102-104]	E-4031 (7–1250 nM)[104,105,108-111] BeKm-1 (3–12 nM)[106-110] ergtoxin (4.5–17 nM)[107,109] LY97241 (2.2–19 nM)[111,112]	mallotoxin (0.5 μM)[114] PD-118057 (3.1 μM)[115] ICA-105574 (0.5 μM)[108]	membrane potential[116] PKA[119,120]
KCNH5	$K_v10.2$		LY97241 (1.5 μM)[113]		membrane potential[97] PKC[97]
KCNT1	$K_{Ca}4.1$	180[122]	bepridil (1 μM)[125] quinidine (90 μM)[125]	bithionol (0.8 μM)[125] niclosamide (2.9 μM)[126] loxapine (4.4 μM)[126] niflumic acid (2.7 mM)[127]	membrane potential[121,122] Ca^{2+} [121] Na^+ [122,123] Cl^- [123] PKC[130]
KCNT2	$K_{Ca}4.2$	140[122]	quinidine[122] isoflurane[128]	meclofenamic acid (80 μM)[127] flufenamic acid (1.1–1.4 mM)[127,129] niflumic acid (2.1 mM)[127,129]	membrane potential[122] Na^+ [122,130] Cl^- [122] intracellular ATP[122] PKC[130]
KCNK5	$K_{2P}5.1$	50–78[133,136,137]	quinine (22 μM)[133] clofilium (25 μM)[138] bupivacaine (26 μM)[139] ropivacaine (95 μM)[139]	halothane, isoflurane, chloroform[140]	extracellular pH[133,138,140,141] PKC[140] osmolality[138]

kinase.[18,29,34] In addition, ATP/UTP was shown to regulate $K_{Ca}3.1$ channels via purinergic receptors in pancreatic cell lines and rat pancreatic duct cells.[10,12,24,35] Both $P2Y_2$ and $P2Y_4$ receptors upregulated $K_{Ca}3.1$ activity in the *Xenopus* oocyte expression system.[11] Importantly, luminal ATP/UTP, most likely delivered by secreting acini,[36,37] was reported to stimulate ductal secretion.[24,35,38-41]

The physiological role of $K_{Ca}3.1$ channels in pancreatic secretion could be also investigated with respect to secretin, which acts predominantly via the cAMP/cAMP-dependent protein kinase (PKA) signaling pathway, however, until this becomes available, we need to resort to studies on other cell types. A membrane-associated PKA has been proposed to activate $K_{Ca}3.1$ channels

in human erythrocytes, the T84 human colonic crypt cell line, and rat submandibular acinar cells.[19,42,43] Interestingly, the PKA consensus phosphorylation site at serine 334 in $K_{Ca}3.1$ channels was not involved in PKA-dependent activation.[43] In contrast to these studies, heterologously expressed $K_{Ca}3.1$ channels were not affected by PKA activators and/or inhibitors,[29,44] or were inhibited by the catalytic subunit of PKA.[45] Given these contradictory results, it is tempting to speculate that $K_{Ca}3.1$ channels may be activated via the phosphorylation of a closely associated protein, the expression of which is tissue-specific. One candidate for this protein is A-kinase anchoring protein (AKAP), which is able to scaffold PKA and components of cAMP signaling pathways, including G protein-coupled receptors and ion channels.[46]

In addition to transepithelial transport, $K_{Ca}3.1$ channels were also shown to be stimulated by cell swelling, which triggered regulatory volume decreases.[47,48] Notably, *KCNN4* mRNA levels were upregulated in primary pancreatic tumors, and the growth of ductal adenocarcinoma cell lines in vitro was inhibited by blockers of $K_{Ca}3.1$ channels, which indicated that these were correlated with the proliferation of pancreatic cancer.[49]

KCNMA1 ($K_{Ca}1.1$, Slo1, α-subunit of BK) and KCNMB (β-subunits)

Tissue expression

The *KCNMA1* coding $K_{Ca}1.1$ (Slo1) protein was cloned from brain and skeletal muscle.[50] Functional expression of the *KCNMA1* gene has been demonstrated in the colon,[51] salivary acini,[17] pancreatic acini,[52] and pancreatic ducts.[11,53] The $K_{Ca}1.1$ protein is located in the luminal membrane of colonic epithelia,[51,54] salivary acini and ducts,[27,55] and pancreatic ducts.[53] It is noteworthy that there was no labeling of the basolateral membrane of guinea-pig pancreatic duct cells, although the first recordings of maxi-K^+ currents were made on the basolateral membrane of rat pancreatic ducts.[7] Venglovecz et al.[53] proposed that luminal $K_{Ca}1.1$ channels, which are activated by bile acids in the lumen, regulate HCO_3^- secretion in pancreatic ducts. Nevertheless, experiments on $K_{Ca}1.1$ regulation have also indicated that some channels may be confined to the basolateral membrane (see below). Luminal $K_{Ca}1.1$ channels in the distal colon were shown to be responsible for resting and stimulated Ca^{2+}-activated K^+ secretion.[51]

Channel properties

$K_{Ca}1.1$ channels have the largest single-channel conductance of all K^+ selective channels: 100–270 pS in symmetrical 150 mM KCl.[50,56] Maxi-K^+ currents in isolated rat pancreatic duct cells had a conductance of 170–180 pS.[7,13] Regarding pharmacology, the α-subunit of $K_{Ca}1.1$ was inhibited by tetraethylammonium, charybdotoxin, iberiotoxin, and paxilline with K_i values of 0.14 mM, 1–31 nM, 1–9 nM, and 2–9 nM, respectively.[50,57-62] The α-subunit of $K_{Ca}1.1$ was also activated by NS1608 and NS11021 with K_d values of 2 μM and 0.4 μM, respectively.[60,63] Interestingly, dehydrosoyasaponin I (DHS-I) activated the α-subunit of $K_{Ca}1.1$ only if co-expressed with the β1-subunit, an auxiliary protein for $K_{Ca}1.1$ channels.[57]

Regulation

Significant diversity has been reported in the functional characteristics of $K_{Ca}1.1$ channels. It is well established that $K_{Ca}1.1$ channels are activated by membrane depolarization alone, intracellular Ca^{2+} alone, or synergistically by depolarization and Ca^{2+}.[7,50,56,64] The single-channel open probability of $K_{Ca}1.1$ channels markedly increased when the cytoplasmic face of a patch membrane was exposed to 10 μM Ca^{2+} and voltage was changed over a range of –60 to +80 mV. Under these conditions, the half-maximal voltage ($V_{1/2}$) was +23 mV in 10 μM Ca^{2+};[50] however, these were unphysiological conditions for pancreatic ducts. Importantly, maxi-K^+ channels on pancreatic duct cells were activated by much lower Ca^{2+} concentrations. For example, maxi-K^+ channels exposed to 3 μM Ca^{2+} reached $V_{1/2}$ at –4 mV.[7] This difference indicated that the β-subunit exists in pancreatic duct cells. Maxi-K^+ channels on *Xenopus* oocytes that heterologously expressed both the α – and β1-subunits of $K_{Ca}1.1$ proteins were about 10-fold more sensitive to activation by voltage and Ca^{2+} concentration than channels composed of the α-subunit alone.[57] Indeed, *KCNMB1* coding the β1 subunit was detected in isolated pancreatic ducts.[11]

Interestingly, UTP was shown to inhibit $K_{Ca}1.1$ channels via the $P2Y_2$ receptor,[11] and appeared to lead to a decrease in secretion. The basolateral application of ATP/UTP inhibited K^+ conductance in rat duct cells and secretion in guinea-pig ducts and human duct cell monolayers.[35,39,40] These results collectively indicated that $P2Y_2$ receptors on the basolateral membrane appeared to downregulate secretion via $K_{Ca}1.1$ channels in the ductal system.

Regarding the cAMP/PKA signaling pathway, cAMP-dependent phosphorylation can also activate maxi-K^+ channels on pancreatic duct cells.[7] The functional response of $K_{Ca}1.1$ channels to PKA phosphorylation depends on the splice-variant of the α-subunit. For example, PKA was shown to activate the ZERO splice variant, whereas PKA inhibited the STREX variant. PKA activation of the ZERO variant requires a conserved C-terminal PKA site.[65] Indeed, the ZERO splice variant has been shown to conduct adrenaline-induced K^+ secretion in the distal colon.[66]

KCNQ1 ($K_v7.1$, KVLQT1) and KCNE1 (minK)

Tissue expression

The *KCNQ1* coding $K_v7.1$ protein was cloned from the heart.[67] Functional expression of the *KCNQ1* gene has also been demonstrated in the kidney, stomach, small intestine, colon,[68-71] pancreatic acini,[69,72,73] and pancreatic ducts.[13] Immunoreactivity of the $K_v7.1$ protein was reported in the parietal cells of the stomach, in the basolateral membrane of small intestinal and colonic crypt cells,[69,74,75] and in acinar and duct cells of the pancreas.[13,69] $K_v7.1$ resides in the tubulovesicular and canalicular membranes of gastric parietal cells together with $H^+–K^+$-pumps and participates in gastric acid secretion.[71,74,75] $K_v7.1$ was localized in the luminal membrane of pancreatic duct cells,[13] and may be involved in cell volume regulation during purinergic stimulation in epithelial transport,[76,77] and/or may potentially be associated with $H^+–K^+$-pumps expressed by pancreatic ducts.[4]

The $K_v7.1$ protein can assemble with the *KCNE* family of regulatory β-subunits to fulfill various physiological functions. For example, minK coded by the *KCNE1* gene has been shown to modify $K_v7.1$ activity by increasing unitary conductance, slowing activation, causing a right shift in the voltage dependence of activation, and modulating pharmacology.[78-82] It is worth noting that the acidification of cytosolic pH increased $K_v7.1$–minK, but decreased $K_v7.1$ currents, whereas alkalinization decreased $K_v7.1$–minK, but increased $K_v7.1$ currents.[83] Indeed, the whole pancreas expresses *KCNE1* and *KCNE2* genes.[84,85] The $K_v7.1$ current was shown to be strongly diminished and membrane targeting of the $K_v7.1$ protein was impaired in acinar cells in *KCNE1* knockout mice.[69] The expression and function of *KCNE* in duct cells has not yet been investigated.

Channel properties

$K_v7.1$ channels have very small conductance. Noise analysis revealed estimated single-channel conductances of 0.7–4 pS.[80,81] Small conductance K^+ channels had 1 pS and were inhibited by chromanol 293B, a $K_v7.1$ blocker, in the basolateral membrane of rat pancreatic acinar cells.[73] Chromanol 293B inhibited α-subunit of $K_v7.1$ with K_i values of 10–41 μM in *Xenopus* oocytes and mammalian expression systems.[68,82,86,87] Importantly, *KCNE* β-subunits increase the sensitivity of $K_v7.1$ to chromanol 293B. K_i values for $K_v7.1$/KCNE1, $K_v7.1$/KCNE2 and $K_v7.1$/KCNE3 were 3–10 μM, 0.4 μM, and 3–4 μM, respectively.[68,70,82,86,87] Voltage-gated K^+ currents in pancreatic acinar cells were shown to be inhibited by chromanol 293B with a K_i value of 3 μM.[72] This result supports voltage-gated K^+ channels being composed of $K_v7.1$ and *KCNE1* β-subunit in acinar cells. Azimilide inhibited $K_v7.1$ and $K_v7.1$/KCNE1 in the same manner as chromanol 293B with K_i values of 77 μM and 5.6 μM, respectively.[86] In contrast, XE991 inhibited $K_v7.1$ and $K_v7.1$/KCNE1 with K_i values of 0.8 μM and 11 μM, respectively.[88] Mefloquine inhibited $K_v7.1$/KCNE1 with a K_i value of 0.9 μM.[89] DIDS and mefenamic acid activated $K_v7.1$/KCNE1, but not $K_v7.1$.[86] On the other hand, L-364,373 activated $K_v7.1$, but did not affect $K_v7.1$/KCNE1.[90]

Regulation

Regarding regulation, voltage-gated $K_v7.1$ channels are known to be regulated by the cAMP signaling pathway.[91] In addition, AKAPs are required for cAMP regulation of recombinant $K_v7.1$ channels in mammalian cell lines.[92] Interestingly, a K^+ current was elicited by cAMP stimulation in CFTR-transfected, but not untransfected CFPAC-1 cells derived from a cystic fibrosis patient with deletion in Phe-508 in CFTR.[93] AKAPs also mediate PKA compartmentalization with CFTR;[94] therefore, these findings imply that functional CFTR regulates the $K_v7.1$ channel, presumably in the luminal membrane of pancreatic duct cells.

KCNH2 ($K_v11.1$, HERG) and *KCNH5* ($K_v10.2$, EAG2)

Tissue expression

The *KCNH2* coding $K_v11.1$ (HERG) protein was isolated from the hippocampal cDNA library.[95] Functional expression of the *KCNH2* gene has been demonstrated in colon carcinoma cells.[96] Immunoreactivity of the $K_v11.1$ protein was also reported in colon carcinoma cells[96] and the luminal membrane of pancreatic duct cells.[13] The *KCNH5* coding $K_v10.2$ (EAG2) protein was identified in the thalamus and was expressed in the brain, testes, skeletal muscle, heart, placenta, lung, liver, and at low levels in the kidney and whole pancreas.[97,98] Notably, $K_v10.2$ was shown to promote medulloblastoma tumor progression by regulating cell volume dynamics.[99] *KCNH2* and *KCNH5* are clearly expressed in rodent and human pancreatic duct cells.[13] However, the physiological or potentially pathophysiological role of $K_v11.1$ and $K_v10.2$ channels remains unclear. The related $K_v10.1$ (*KCNH1*) channel has been shown to be upregulated in several cancers including pancreatic cancer, based on studies of human pancreatic adenocarcinoma cell lines.[100,101]

Channel properties

$K_v11.1$ channels have small conductance of 10–13 pS.[102-104] Regarding pharmacology, $K_v11.1$ was inhibited by E-4031, BeKm-1, and ergtoxin with K_i values of 7–1250 nM, 3–12 nM, and 4.5–17 nM, respectively.[104-111] $K_v11.1$ channels formed with *KCNE2* were about 2-fold more sensitive to E-4031.[104] LY97241 was shown to inhibit $K_v10.2$ and $K_v11.1$ currents with K_i values of 1.5 μM and 2.2–19 nM, respectively.[111-113] $K_v11.1$ currents were also activated by mallotoxin, PD-118057, and ICA-105574 with K_d values of 0.5 μM, 3.1 μM, and 0.5 μM, respectively.[108,114,115]

Regulation

$K_v11.1$ currents were activated at voltages more positive than –50 mV and $V_{1/2}$ was – 15.1 mV,[116] whereas $K_v10.2$ currents were activated at around – 100 mV and $V_{1/2}$ was – 35.5 mV.[97] However, a 14–3–3 protein was associated with $K_v11.1$ in a phosphorylation-dependent manner at specific PKA sites and shifted $V_{1/2}$ in a hyperpolarizing direction by – 11.1 mV.[117] $K_v11.1$ may exist in a macromolecular signaling complex that includes 14–3–3 proteins and possibly AKAPs.[118] Importantly, the $K_v11.1$ protein can also assemble with *KCNE1* or *KCNE2* regulatory β-subunits.[103,104] Regarding inhibition, phorbol 12-myristate 13-acetate (PMA), an activator of protein kinase C (PKC), produced a potent dose-dependent block of $K_v10.2$ or $K_v11.1$ currents.[97,119] In addition, $K_v11.1$ currents were reduced by the cAMP-specific phosphodiesterase inhibitor Ro-20–1724 or the adenylate cyclase activator forskolin, which were shown to result in increased cAMP levels and PKA stimulation.[120]

KCNT1 ($K_{Ca}4.1$, Slo2.2, Slack) and *KCNT2* ($K_{Ca}4.2$, Slo2.1, Slick)

Tissue expression

KCNT1 ($K_{Ca}4.1$, Slo2.2, or Slack), which encodes for the Na^+-activated K^+ channel, was isolated from the brain cDNA library.[121] *KCNT1* and *KCNT2* ($K_{Ca}4.2$, Slo2.1, or Slick) are expressed in the heart, kidney and testis, as well as in the brain.[121-123] The functional expression of $K_{Ca}4.1$ has been demonstrated in the basolateral membrane of the thick ascending limbs of Henle's loop.[124] Pancreatic duct cells also expressed *KCNT1* and *KCNT2*.[13] Interestingly, the expression pattern of *KCNT1* and *KCNT2* was different between Capan-1 cells expressing functional CFTR channels and CFPAC-1 cells derived from a cystic fibrosis patient with a mutation in CFTR. Capan-1 cells express *KCNT1*, but not *KCNT2*, while CFPAC-1 cells express *KCNT2*,

but not *KCNT1*. This discrepancy indicates that the expression of *KCNT1* and *KCNT2* channels is in some way associated with the expression of functional CFTR. However, the function of these K$^+$ channels in pancreatic duct cells remains to be investigated.

Channel properties

$K_{Ca}4.1$ and $K_{Ca}4.2$ channels have large conductances of 180 pS and 140 pS in symmetrical 130 mM KCl.[122] In the basolateral membrane of the thick ascending limbs of Henle's loop, Na$^+$-activated K$^+$ channels had a conductance of 140–180 pS.[124] Regarding pharmacology, $K_{Ca}4.1$ was inhibited by bepridil and quinidine with K_i values of 1 μM and 90 μM, respectively.[125] $K_{Ca}4.1$ was activated by bithionol, niclosamide, loxapine, and niflumic acid with K_d values of 0.8 μM, 2.9 μM, 4.4 μM, and 2.7 mM, respectively.[125-127] $K_{Ca}4.2$ was inhibited by 1 mM quinidine and isoflurane,[122,128] and was activated by meclofenamic acid, flufenamic acid, and niflumic acid with K_d values of 80 μM, 1.1–1.4 mM, and 2.1 mM, respectively.[127,129]

Regulation

$K_{Ca}4.1$ was shown to be unusually inhibited by intracellular Ca^{2+} at 1 μM.[121] However, $K_{Ca}4.1$ may co-assemble with $K_{Ca}1.1$ subunits to generate Ca^{2+}-activated K$^+$ channels.[121] $K_{Ca}4.1$ and $K_{Ca}4.2$ channels were reported to be activated by intracellular Na$^+$ and K_d values of 41 mM and 89 mM in the presence of 30 mM internal Cl$^-$, respectively.[122] These channels were also activated by intracellular Cl$^-$ or synergistically by Na$^+$ and Cl$^-$.[122,123] Intracellular ATP inhibited $K_{Ca}4.2$ directly, via the presence of a consensus ATP binding motif.[122] A similar ATP binding motif has not been demonstrated in the $K_{Ca}4.1$ sequences.[122,124] Interestingly, the PKC activator PMA increased $K_{Ca}4.1$ currents, but inhibited $K_{Ca}4.2$ currents.[130]

KCNK5 (K$_{2P}$5.1, TASK-2)

Tissue expression

Two-pore domain K$^+$ channels (K$_{2P}$) generate background K$^+$ currents over the whole membrane potential range.[131] The pH-sensitive K$_{2P}$ subunits (TALK-1, TALK-2 and TASK-2) were shown to be expressed in pancreatic acini.[132] An electrophysiological study indicated that TASK-2 was expressed in HPAF, a human pancreatic ductal adenocarcinoma cell line.[10] *KCNK5* coding TASK-2 (K$_{2P}$5.1) was isolated from the brain cDNA library.[133] *KCNK5* is expressed in the kidney, liver, stomach, small intestine, colon, and pancreatic acinus.[132-134] The functional expression of K$_{2P}$5.1 has been demonstrated in kidney proximal convoluted tubule cells, which could be involved in volume regulation and HCO$_3^-$ transport.[135] Clofilium-sensitive K$^+$ conductance, possibly K$_{2P}$5.1, was located in the luminal membrane of the monolayer of HPAF.[10] pH-sensitive K$^+$ channels on the luminal membrane of pancreatic duct cells may be physiologically relevant in terms of maintaining the electrical driving force for electrogenic HCO$_3^-$ secretion and providing an exit pathway for K$^+$ secretion.

Channel properties

K$_{2P}$5.1 channels have an intermediate conductance of 50–78 pS.[133,136,137] Regarding pharmacology, K$_{2P}$5.1 was inhibited by quinine, clofilium, bupivacaine, and ropivacaine with K_i values

of 22 μM, 25 μM, 26 μM, and 95 μM, respectively.[133,138,139] K$_{2P}$5.1 was activated by halothane, isoflurane, and chloroform, which are volatile anesthetics.[140]

Regulation

K$_{2P}$5.1 is very sensitive to extracellular pH in the physiological range, with a pK_a value of 7.5–8.3.[133,138,140,141] Phorbol 12,13-dibutyrate and PMA, activators of PKC, were shown to potentiate K$_{2P}$5.1 currents in *Xenopus* oocytes.[140] Extracellular ATP activated TASK-like channels (K$_{2P}$3.1 and/or K$_{2P}$5.1), possibly via the P2Y$_{11}$ receptor in thoracic aorta myocytes.[142] P2Y$_{11}$ receptors were reported to be expressed on the basolateral membrane of canine pancreatic duct epithelia, which increased cAMP and I_{sc}.[143] The K$_{2P}$5.1 channel is also osmosensitive and participates in cell volume regulation.[138] Therefore, pH-sensitive K$^+$ channels may be important on both the luminal (alkaline) and basolateral (acid) membranes of pancreatic ducts.

Potassium Channels in Pancreatic Cancer

Ion channels have been associated with the malignant phenotype of cancer cells, as well as contributing to virtually all basic cellular processes, including crucial roles in maintaining tissue homeostasis such as proliferation, differentiation, and apoptosis.[144] Several potassium channels have been suggested as the hallmarks of cancer,[145] including pancreatic duct adenocarcinoma.[144] For example, $K_{Ca}3.1$ channels have been correlated with the proliferation of pancreatic cancer.[49] In addition, the expression of G protein-activated inward rectifier potassium channel 1 (K$_{ir}$3.1) was markedly higher in pancreatic adenocarcinomas than in a normal pancreas, whereas K$_v$1.3 expression was decreased in pancreatic adenocarcinomas. Downregulation in the expression of K$_v$1.3 has been associated with metastatic tumors.[146] K$_v$1.5 was also shown to be highly expressed in pancreatic adenocarcinomas.[147] Furthermore, a specific monoclonal antibody that inhibits the function of K$_v$10.1 (EAG1) reduced tumor growth of BxPC3, a human pancreas adenocarcinoma cell line, which implicates this channel in cancer progression.[100] Altered pH homeostasis is known to be one of the key hallmarks of cancer.[148,149] Thus, pH-sensitive K$_{2P}$ channels may also play a role in pancreatic adenocarcinoma. The human duct adenocarcinoma cell line, HPAF cells, were reported to express K$_{2P}$5.1 channels.[10] However, its contribution to cancer progression is still unknown. Although further studies on K$^+$ channels in pancreatic cancer must be performed, some candidates, such as K$_v$10.1, already have the potential to be diagnostic tools and therapeutic targets.[101]

Concluding Remarks

This review described the current status on the molecular basis for a number of K$^+$ channels found in pancreatic ducts. Electrophysiological studies on ducts and duct cells using microelectrode, patch-clamp, and Ussing chamber methods showed how some of these K$^+$ channels contribute to physiological processes in ductal secretion by providing the driving forces for anion transport and as partial accompanying partners in

secretion. Future studies are needed to verify the localization of K⁺ channels to a polarized ductal epithelium and affirm their physiological function in secretion or associated cell processes such as cell volume regulation, as well as their participation in cell proliferation and apoptosis. The pancreas and especially the ductal epithelium are involved in a number of diseases including cystic fibrosis and pancreatitis.[150] Some target therapies should include K⁺ channel openers to maintain or upregulate pancreatic secretion. Our knowledge regarding the role of K⁺ channels in duct cell homeostasis remains relatively sparse. Because some K⁺ channels are being regarded as the hallmark of cancer progression and emerging studies on pancreatic adenocarcinoma foreshadow similar trends, more knowledge is required in this area before specific K⁺ channel openers or inhibitors can be used in the treatment of pancreatic diseases.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

References

1. Steward MC, Ishiguro H, Case RM. Mechanisms of bicarbonate secretion in the pancreatic duct. Annu Rev Physiol 2005; 67:377-409; PMID:15709963; http://dx.doi.org/10.1146/annurev.physiol.67.031103.153247

2. Novak I. Purinergic signalling in epithelial ion transport: regulation of secretion and absorption. Acta Physiol (Oxf) 2011; 202:501-22; PMID:21073662; http://dx.doi.org/10.1111/j.1748-1716.2010.02225.x

3. Lee MG, Ohana E, Park HW, Yang D, Muallem S. Molecular mechanism of pancreatic and salivary gland fluid and HCO₃ secretion. Physiol Rev 2012; 92:39-74; PMID:22298651; http://dx.doi.org/10.1152/physrev.00011.2011

4. Novak I, Wang J, Henriksen KL, Haanes KA, Krabbe S, Nitschke R, Hede SE. Pancreatic bicarbonate secretion involves two proton pumps. J Biol Chem 2011; 286:280-9; PMID:20978133; http://dx.doi.org/10.1074/jbc.M110.136382

5. Heitzmann D, Warth R. Physiology and pathophysiology of potassium channels in gastrointestinal epithelia. Physiol Rev 2008; 88:1119-82; PMID:18626068; http://dx.doi.org/10.1152/physrev.00020.2007

6. Novak I, Greger R. Electrophysiological study of transport systems in isolated perfused pancreatic ducts: properties of the basolateral membrane. Pflügers Arch 1988; 411:58-68; PMID:3353213; http://dx.doi.org/10.1007/BF00581647

7. Gray MA, Greenwell JR, Garton AJ, Argent BE. Regulation of maxi-K⁺ channels on pancreatic duct cells by cyclic AMP-dependent phosphorylation. J Membr Biol 1990; 115:203-15; PMID:1695685; http://dx.doi.org/10.1007/BF01868636

8. Novak I, Greger R. Effect of bicarbonate on potassium conductance of isolated perfused rat pancreatic ducts. Pflügers Arch 1991; 419:76-83; PMID:1945765; http://dx.doi.org/10.1007/BF00373750

9. Ishiguro H, Steward MC, Sohma Y, Kubota T, Kitagawa M, Kondo T, Case RM, Hayakawa T, Naruse S. Membrane potential and bicarbonate secretion in isolated interlobular ducts from guinea-pig pancreas. J Gen Physiol 2002; 120:617-28; PMID:12407075; http://dx.doi.org/10.1085/jgp.20028631

10. Fong P, Argent BE, Guggino WB, Gray MA. Characterization of vectorial chloride transport pathways in the human pancreatic duct adenocarcinoma cell line HPAF. Am J Physiol Cell Physiol 2003; 285:C433-45; PMID:12711595; http://dx.doi.org/10.1152/ajpcell.00509.2002

11. Hede SE, Amstrup J, Klaerke DA, Novak I. P2Y₂ and P2Y₄ receptors regulate pancreatic Ca(²⁺)-activated K⁺ channels differently. Pflügers Arch 2005; 450:429-36; PMID:16075244; http://dx.doi.org/10.1007/s00424-005-1433-3

12. Jung SR, Kim K, Hille B, Nguyen TD, Koh DS. Pattern of Ca²⁺ increase determines the type of secretory mechanism activated in dog pancreatic duct epithelial cells. J Physiol 2006; 576:163-78; PMID:16857709; http://dx.doi.org/10.1113/jphysiol.2006.114876

13. Hayashi M, Wang J, Hede SE, Novak I. An intermediate-conductance Ca²⁺-activated K⁺ channel is important for secretion in pancreatic duct cells. Am J Physiol Cell Physiol 2012; 303:C151-9; PMID:22555847; http://dx.doi.org/10.1152/ajpcell.00089.2012

14. Joiner WJ, Wang LY, Tang MD, Kaczmarek LK. hSK4, a member of a novel subfamily of calcium-activated potassium channels. Proc Natl Acad Sci U S A 1997; 94:11013-8; PMID:9380751; http://dx.doi.org/10.1073/pnas.94.20.11013

15. Ishii TM, Silvia C, Hirschberg B, Bond CT, Adelman JP, Maylie J. A human intermediate conductance calcium-activated potassium channel. Proc Natl Acad Sci U S A 1997; 94:11651-6; PMID:9326665; http://dx.doi.org/10.1073/pnas.94.21.11651

16. Warth R, Hamm K, Bleich M, Kunzelmann K, von Hahn T, Schreiber R, Ullrich E, Mengel M, Trautmann N, Kindle P, et al. Molecular and functional characterization of the small Ca(²⁺)-regulated K⁺ channel (rSK4) of colonic crypts. Pflügers Arch 1999; 438:437-44; PMID:10519135; http://dx.doi.org/10.1007/s004240051059

17. Nehrke K, Quinn CC, Begenisich T. Molecular identification of Ca²⁺-activated K⁺ channels in parotid acinar cells. Am J Physiol Cell Physiol 2003; 284:C535-46; PMID:12388098; http://dx.doi.org/10.1152/ajpcell.00044.2002

18. Takahata T, Hayashi M, Ishikawa T. SK4/IK1-like channels mediate TEA-insensitive, Ca²⁺-activated K⁺ currents in bovine parotid acinar cells. Am J Physiol Cell Physiol 2003; 284:C127-44; PMID:12388063; http://dx.doi.org/10.1152/ajpcell.00250.2002

19. Hayashi M, Kunii C, Takahata T, Ishikawa T. ATP-dependent regulation of SK4/IK1-like currents in rat submandibular acinar cells: possible role of cAMP-dependent protein kinase. Am J Physiol Cell Physiol 2004; 286:C635-46; PMID:14602578; http://dx.doi.org/10.1152/ajpcell.00283.2003

20. Furness JB, Robbins HL, Selmer IS, Hunne B, Chen MX, Hicks GA, Moore S, Neylon CB. Expression of intermediate conductance potassium channel immunoreactivity in neurons and epithelial cells of the rat gastrointestinal tract. Cell Tissue Res 2003; 314:179-89; PMID:14513356; http://dx.doi.org/10.1007/s00441-003-0808-z

21. Joiner WJ, Basavappa S, Vidyasagar S, Nehrke K, Krishnan S, Binder HJ, Boulpaep EL, Rajendran VM. Active K⁺ secretion through multiple K꜀ₐ-type channels and regulation by IK꜀ₐ channels in rat proximal colon. Am J Physiol Gastrointest Liver Physiol 2003; 285:G185-96; PMID:12606302

22. Ubels JL, Hoffman HM, Srikanth S, Resau JH, Webb CP. Gene expression in rat lacrimal gland duct cells collected using laser capture microdissection: evidence for K⁺ secretion by duct cells. Invest Ophthalmol Vis Sci 2006; 47:1876-85; PMID:16638994; http://dx.doi.org/10.1167/iovs.05-0363

23. Thompson-Vest N, Shimizu Y, Hunne B, Furness JB. The distribution of intermediate-conductance, calcium-activated, potassium (IK) channels in epithelial cells. J Anat 2006; 208:219-29; PMID:16441566; http://dx.doi.org/10.1111/j.1469-7580.2006.00515.x

24. Wang J, Haanes KA, Novak I. Purinergic regulation of CFTR and Ca(²⁺)-activated Cl(⁻) channels and K(⁺) channels in human pancreatic duct epithelium. Am J Physiol Cell Physiol 2013; 304:C673-84; PMID:23364268; http://dx.doi.org/10.1152/ajpcell.00196.2012

25. Sewell WA, Young JA. Secretion of electrolytes by the pancreas of the anaestetized rat. J Physiol 1975; 252:379-96; PMID:1206529

26. Nanda Kumar NS, Singh SK, Rajendran VM. Mucosal potassium efflux mediated via Kcnn4 channels provides the driving force for electrogenic anion secretion in colon. Am J Physiol Gastrointest Liver Physiol 2010; 299:G707-14; PMID:20616305; http://dx.doi.org/10.1152/ajpgi.00101.2010

27. Almassy J, Won JH, Begenisich TB, Yule DI. Apical Ca²⁺-activated potassium channels in mouse parotid acinar cells. J Gen Physiol 2012; 139:121-33; PMID:22291145; http://dx.doi.org/10.1085/jgp.201110718

28. Jensen BS, Strøbæk D, Christophersen P, Jørgensen TD, Hansen C, Silahtaroglu A, Olesen SP, Ahring PK. Characterization of the cloned human intermediate-conductance Ca²⁺-activated K⁺ channel. Am J Physiol 1998; 275:C848-56; PMID:9730970

29. von Hahn T, Thiele I, Zingaro L, Hamm K, Garcia-Alzamora M, Köttgen M, Bleich M, Warth R. Characterisation of the rat SK4/IK1 K(⁺) channel. Cell Physiol Biochem 2001; 11:219-30; PMID:11509830; http://dx.doi.org/10.1159/000051936

30. Wulff H, Miller MJ, Hänsel W, Grissmer S, Cahalan MD, Chandy KG. Design of a potent and selective inhibitor of the intermediate-conductance Ca²⁺-activated K⁺ channel, IKCa1: a potential immunosuppressant. Proc Natl Acad Sci U S A 2000; 97:8151-6; PMID:10884437; http://dx.doi.org/10.1073/pnas.97.14.8151

31. Wulf A, Schwab A. Regulation of a calcium-sensitive K⁺ channel (cIK1) by protein kinase C. J Membr Biol 2002; 187:71-9; PMID:12029379; http://dx.doi.org/10.1007/s00232-001-0149-3

32. Castle NA, London DO, Creech C, Fajloun Z, Stocker JW, Sabatier JM. Maurotoxin: a potent inhibitor of intermediate conductance Ca²⁺-activated potassium channels. Mol Pharmacol 2003; 63:409-18; PMID:12527813; http://dx.doi.org/10.1124/mol.63.2.409

33. Singh S, Syme CA, Singh AK, Devor DC, Bridges RJ. Benzimidazolone activators of chloride secretion: potential therapeutics for cystic fibrosis and chronic obstructive pulmonary disease. J Pharmacol Exp Ther 2001; 296:600-11; PMID:11160649

34. Fanger CM, Ghanshani S, Logsdon NJ, Rauer H, Kalman K, Zhou J, Beckingham K, Chandy KG, Cahalan MD, Aiyar J. Calmodulin mediates calcium-dependent activation of the intermediate conductance K_{Ca} channel, *IKCa1*. J Biol Chem 1999; 274:5746-54; PMID:10026195; http://dx.doi.org/10.1074/jbc.274.9.5746

35. Hede SE, Amstrup J, Christoffersen BC, Novak I. Purinoceptors evoke different electrophysiological responses in pancreatic ducts. P2Y inhibits K(+) conductance, and P2X stimulates cation conductance. J Biol Chem 1999; 274:31784-91; PMID:10542200; http://dx.doi.org/10.1074/jbc.274.45.31784

36. Sørensen CE, Novak I. Visualization of ATP release in pancreatic acini in response to cholinergic stimulus. Use of fluorescent probes and confocal microscopy. J Biol Chem 2001; 276:32925-32; PMID:11387334; http://dx.doi.org/10.1074/jbc.M103313200

37. Haanes KA, Novak I. ATP storage and uptake by isolated pancreatic zymogen granules. Biochem J 2010; 429:303-11; PMID:20441565; http://dx.doi.org/10.1042/BJ20091337

38. Hug M, Pahl C, Novak I. Effect of ATP, carbachol and other agonists on intracellular calcium activity and membrane voltage of pancreatic ducts. Pflügers Arch 1994; 426:412-8; PMID:7517031; http://dx.doi.org/10.1007/BF00388304

39. Ishiguro H, Naruse S, Kitagawa M, Hayakawa T, Case RM, Steward MC. Luminal ATP stimulates fluid and HCO_3^- secretion in guinea-pig pancreatic duct. J Physiol 1999; 519:551-8; PMID:10457070; http://dx.doi.org/10.1111/j.1469-7793.1999.0551m.x

40. Szűcs A, Demeter I, Burghardt B, Óvári G, Case RM, Steward MC, Varga G. Vectorial bicarbonate transport by Capan-1 cells: a model for human pancreatic ductal secretion. Cell Physiol Biochem 2006; 18:253-64; PMID:17167230; http://dx.doi.org/10.1159/000097672

41. Wang J, Novak I. Ion transport in human pancreatic duct epithelium, Capan-1 cells, is regulated by secretin, VIP, acetylcholine, and purinergic receptors. Pancreas 2013; 42:452-60; PMID:22982819; http://dx.doi.org/10.1097/MPA.0b013e318264c302

42. Pellegrino M, Pellegrini M. Modulation of Ca^{2+}-activated K$^+$ channels of human erythrocytes by endogenous cAMP-dependent protein kinase. Pflügers Arch 1998; 436:749-56; PMID:9716709; http://dx.doi.org/10.1007/s004240050698

43. Gerlach AC, Gangopadhyay NN, Devor DC. Kinase-dependent regulation of the intermediate conductance, calcium-dependent potassium channel, hIK1. J Biol Chem 2000; 275:585-98; PMID:10617655; http://dx.doi.org/10.1074/jbc.275.1.585

44. Schrøder RL, Jensen BS, Strøbæk D, Olesen SP, Christophersen P. Activation of the human, intermediate-conductance, Ca^{2+}-activated K$^+$ channel by methylxanthines. Pflügers Arch 2000; 440:809-18; PMID:11041545; http://dx.doi.org/10.1007/s004240000364

45. Neylon CB, D'Souza T, Reinhart PH. Protein kinase A inhibits intermediate conductance Ca^{2+}-activated K$^+$ channels expressed in *Xenopus* oocytes. Pflügers Arch 2004; 448:613-20; PMID:15243742; http://dx.doi.org/10.1007/s00424-004-1302-5

46. Dessauer CW. Adenylyl cyclase–-A-kinase anchoring protein complexes: the next dimension in cAMP signaling. Mol Pharmacol 2009; 76:935-41; PMID:19684092; http://dx.doi.org/10.1124/mol.109.059345

47. Vandorpe DH, Shmukler BE, Jiang L, Lim B, Maylie J, Adelman JP, de Franceschi L, Cappellini MD, Brugnara C, Alper SL. cDNA cloning and functional characterization of the mouse Ca^{2+}-gated K$^+$ channel, mIK1. Roles in regulatory volume decrease and erythroid differentiation. J Biol Chem 1998; 273:21542-53; PMID:9705284; http://dx.doi.org/10.1074/jbc.273.34.21542

48. Hoffmann EK, Lambert IH, Pedersen SF. Physiology of cell volume regulation in vertebrates. Physiol Rev 2009; 89:193-277; PMID:19126758; http://dx.doi.org/10.1152/physrev.00037.2007

49. Jäger H, Dreker T, Buck A, Giehl K, Gress T, Grissmer S. Blockage of intermediate-conductance Ca^{2+}-activated K$^+$ channels inhibit human pancreatic cancer cell growth in vitro. Mol Pharmacol 2004; 65:630-8; PMID:14978241; http://dx.doi.org/10.1124/mol.65.3.630

50. Butler A, Tsunoda S, McCobb DP, Wei A, Salkoff L. *mSlo*, a complex mouse gene encoding "maxi" calcium-activated potassium channels. Science 1993; 261:221-4; PMID:7687074; http://dx.doi.org/10.1126/science.7687074

51. Sausbier M, Matos JE, Sausbier U, Beranek G, Arntz C, Neuhuber W, Ruth P, Leipziger J. Distal colonic K(+) secretion occurs *via* BK channels. J Am Soc Nephrol 2006; 17:1275-82; PMID:16571783; http://dx.doi.org/10.1681/ASN.2005101111

52. Oshiro T, Takahashi H, Ohsaga A, Ebihara S, Sasaki H, Maruyama Y. Delayed expression of large conductance K$^+$ channels reshaping agonist-induced currents in mouse pancreatic acinar cells. J Physiol 2005; 563:379-91; PMID:15611028; http://dx.doi.org/10.1113/jphysiol.2004.077834

53. Venglovecz V, Hegyi P, Rakonczay Z Jr., Tiszlavicz L, Nardi A, Grunnet M, Gray MA. Pathophysiological relevance of apical large-conductance Ca^{2+}-activated potassium channels in pancreatic duct epithelial cells. Gut 2011; 60:361-9; PMID:20940280; http://dx.doi.org/10.1136/gut.2010.214213

54. Hay-Schmidt A, Grunnet M, Abrahamse SL, Knaus HG, Klaerke DA. Localization of Ca^{2+} – activated big-conductance K$^+$ channels in rabbit distal colon. Pflügers Arch 2003; 446:61-8; PMID:12690464

55. Nakamoto T, Romanenko VG, Takahashi A, Begenisich T, Melvin JE. Apical maxi-K (K_{Ca}1.1) channels mediate K$^+$ secretion by the mouse submandibular exocrine gland. Am J Physiol Cell Physiol 2008; 294:C810-9; PMID:18216162; http://dx.doi.org/10.1152/ajpcell.00511.2007

56. Salkoff L, Butler A, Ferreira G, Santi C, Wei A. High-conductance potassium channels of the SLO family. Nat Rev Neurosci 2006; 7:921-31; PMID:17115074; http://dx.doi.org/10.1038/nrn1992

57. McManus OB, Helms LM, Pallanck L, Ganetzky B, Swanson R, Leonard RJ. Functional role of the β subunit of high conductance calcium-activated potassium channels. Neuron 1995; 14:645-50; PMID:7695911; http://dx.doi.org/10.1016/0896-6273(95)90321-6

58. Gribkoff VK, Lum-Ragan JT, Boissard CG, Post-Munson DJ, Meanwell NA, Starrett JE Jr., Kozlowski ES, Romine JL, Trojnacki JT, Mckay MC, et al. Effects of channel modulators on cloned large-conductance calcium-activated potassium channels. Mol Pharmacol 1996; 50:206-17; PMID:8700114

59. Sanchez M, McManus OB. Paxilline inhibition of the alpha-subunit of the high-conductance calcium-activated potassium channel. Neuropharmacology 1996; 35:963-8; PMID:8938726; http://dx.doi.org/10.1016/0028-3908(96)00137-2

60. Strøbæk D, Christophersen P, Holm NR, Moldt P, Ahring PK, Johansen TE, Olesen SP. Modulation of the Ca^{2+}-dependent K$^+$ channel, *hslo*, by the substituted diphenylurea NS 1608, paxilline and internal Ca^{2+}. Neuropharmacology 1996; 35:903-14; PMID:8938721; http://dx.doi.org/10.1016/0028-3908(96)00096-2

61. Koschak A, Koch RO, Liu J, Kaczorowski GJ, Reinhart PH, Garcia ML, Knaus HG. [125I]Iberiotoxin-D19Y/Y36F, the first selective, high specific activity radioligand for high-conductance calcium-activated potassium channels. Biochemistry 1997; 36:1943-52; PMID:9048582; http://dx.doi.org/10.1021/bi962074m

62. Meera P, Wallner M, Toro L. A neuronal β subunit (KCNMB4) makes the large conductance, voltage – and Ca^{2+}-activated K$^+$ channel resistant to charybdotoxin and iberiotoxin. Proc Natl Acad Sci U S A 2000; 97:5562-7; PMID:10792058; http://dx.doi.org/10.1073/pnas.100118597

63. Bentzen BH, Nardi A, Calloe K, Madsen LS, Olesen SP, Grunnet M. The small molecule NS11021 is a potent and specific activator of Ca^{2+}-activated big-conductance K$^+$ channels. Mol Pharmacol 2007; 72:1033-44; PMID:17636045; http://dx.doi.org/10.1124/mol.107.038331

64. Magleby KL. Gating mechanism of BK (Slo1) channels: so near, yet so far. J Gen Physiol 2003; 121:81-96; PMID:12566537; http://dx.doi.org/10.1085/jgp.20028721

65. Tian L, Duncan RR, Hammond MS, Coghill LS, Wen H, Rusinova R, Clark AG, Levitan IB, Shipston MJ. Alternative splicing switches potassium channel sensitivity to protein phosphorylation. J Biol Chem 2001; 276:7717-20; PMID:11244090; http://dx.doi.org/10.1074/jbc.C000741200

66. Sørensen MV, Sausbier M, Ruth P, Seidler U, Riederer B, Praetorius HA, Leipziger J. Adrenaline-induced colonic K$^+$ secretion is mediated by K_{Ca}1.1 (BK) channels. J Physiol 2010; 588:1763-77; PMID:20351045; http://dx.doi.org/10.1113/jphysiol.2009.181933

67. Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, VanRaay TJ, Shen J, Timothy KW, Vincent GM, de Jager T, et al. Positional cloning of a novel potassium channel gene: *KVLQT1* mutations cause cardiac arrhythmias. Nat Genet 1996; 12:17-23; PMID:8528244; http://dx.doi.org/10.1038/ng0196-17

68. Schroeder BC, Waldegger S, Fehr S, Bleich M, Warth R, Greger R, Jentsch TJ. A constitutively open potassium channel formed by KCNQ1 and KCNE3. Nature 2000; 403:196-9; PMID:10646604; http://dx.doi.org/10.1038/35003200

69. Warth R, Garcia Alzamora M, Kim JK, Zdebik A, Nitschke R, Bleich M, Gerlach U, Barhanin J, Kim SJ. The role of KCNQ1/KCNE1 K$^+$ channels in intestine and pancreas: lessons from the KCNE1 knockout mouse. Pflügers Arch 2002; 443:822-8; PMID:11889581; http://dx.doi.org/10.1007/s00424-001-0751-3

70. Heitzmann D, Grahammer F, von Hahn T, Schmitt-Gräff A, Romeo E, Nitschke R, Gerlach U, Lang HJ, Verrey F, Barhanin J, et al. Heteromeric KCNE2/KCNQ1 potassium channels in the luminal membrane of gastric parietal cells. J Physiol 2004; 561:547-57; PMID:15579540; http://dx.doi.org/10.1113/jphysiol.2004.075168

71. Vallon V, Grahammer F, Volkl H, Sandu CD, Richter K, Rexhepaj R, Gerlach U, Rong Q, Pfeifer K, Lang F. KCNQ1-dependent transport in renal and gastrointestinal epithelia. Proc Natl Acad Sci U S A 2005; 102:17864-9; PMID:16314573; http://dx.doi.org/10.1073/pnas.0505860102

72. Kim SJ, Greger R. Voltage-dependent, slowly activating K$^+$ current (I_{Ks}) and its augmentation by carbachol in rat pancreatic acini. Pflügers Arch 1999; 438:604-11; PMID:10555556; http://dx.doi.org/10.1007/s004240051083

73. Köttgen M, Hoefer A, Kim SJ, Beschorner U, Schreiber R, Hug MJ, Greger R. Carbachol activates a K$^+$ channel of very small conductance in the basolateral membrane of rat pancreatic acinar cells. Pflügers Arch 1999; 438:597-603; PMID:10555555; http://dx.doi.org/10.1007/s004240051082

74. Dedek K, Waldegger S. Colocalization of KCNQ1/KCNE channel subunits in the mouse gastro-intestinal tract. Pflügers Arch 2001; 442:896-902; PMID:11680623; http://dx.doi.org/10.1007/s004240100609

75. Grahammer F, Herling AW, Lang HJ, Schmitt-Gräff A, Wittekindt OH, Nitschke R, Bleich M, Barhanin J, Warth R. The cardiac K⁺ channel KCNQ1 is essential for gastric acid secretion. Gastroenterology 2001; 120:1363-71; PMID:11313306; http://dx.doi.org/10.1053/gast.2001.24053

76. Grunnet M, Jespersen T, MacAulay N, Jørgensen NK, Schmitt N, Pongs O, Olesen SP, Klaerke DA. KCNQ1 channels sense small changes in cell volume. J Physiol 2003; 549:419-27; PMID:12702742; http://dx.doi.org/10.1113/jphysiol.2003.038455

77. Hammami S, Willumsen NJ, Meinild AK, Klaerke DA, Novak I. Purinergic signalling – a possible mechanism for KCNQ1 channel response to cell volume challenges. Acta Physiol (Oxf) 2013; 207:503-15; PMID:22805606; http://dx.doi.org/10.1111/j.1748-1716.2012.02460.x

78. Barhanin J, Lesage F, Guillemare E, Fink M, Lazdunski M, Romey GK. K$_V$LQT1 and lsK (minK) proteins associate to form the I_{Ks} cardiac potassium current. Nature 1996; 384:78-80; PMID:8900282; http://dx.doi.org/10.1038/384078a0

79. Sanguinetti MC, Curran ME, Zou A, Shen J, Spector PS, Atkinson DL, Keating MT. Coassembly of K$_V$ LQT1 and minK (IsK) proteins to form cardiac I_{Ks} potassium channel. Nature 1996; 384:80-3; PMID:8900283; http://dx.doi.org/10.1038/384080a0

80. Sesti F, Goldstein SA. Single-channel characteristics of wild-type I_{Ks} channels and channels formed with two minK mutants that cause long QT syndrome. J Gen Physiol 1998; 112:651-63; PMID:9834138; http://dx.doi.org/10.1085/jgp.112.6.651

81. Yang Y, Sigworth FJ. Single-channel properties of I_{Ks} potassium channels. J Gen Physiol 1998; 112:665-78; PMID:9834139; http://dx.doi.org/10.1085/jgp.112.6.665

82. Lerche C, Seebohm G, Wagner CI, Scherer CR, Dehmelt L, Abitbol I, Gerlach U, Brendel J, Attali B, Busch AE. Molecular impact of MinK on the enantiospecific block of I_{Ks} by chromanols. Br J Pharmacol 2000; 131:1503-6; PMID:11139424; http://dx.doi.org/10.1038/sj.bjp.0703734

83. Unsöld B, Kerst G, Brousos H, Hübner M, Schreiber R, Nitschke R, Greger R, Bleich M. KCNE1 reverses the response of the human K⁺ channel KCNQ1 to cytosolic pH changes and alters its pharmacology and sensitivity to temperature. Pflügers Arch 2000; 441:368-78; PMID:11211125; http://dx.doi.org/10.1007/s004240000434

84. Takumi T, Ohkubo H, Nakanishi S. Cloning of a membrane protein that induces a slow voltage-gated potassium current. Science 1988; 242:1042-5; PMID:3194754; http://dx.doi.org/10.1126/science.3194754

85. Tinel N, Diochot S, Lauritzen I, Barhanin J, Lazdunski M, Borsotto M. M-type KCNQ2-KCNQ3 potassium channels are modulated by the KCNE2 subunit. FEBS Lett 2000; 480:137-41; PMID:11034315; http://dx.doi.org/10.1016/S0014-5793(00)01918-9

86. Busch AE, Busch GL, Ford E, Suessbrich H, Lang HJ, Greger R, Kunzelmann K, Attali B, Stühmer W. The role of the I_{sK} protein in the specific pharmacological properties of the I_{Ks} channel complex. Br J Pharmacol 1997; 122:187-9; PMID:9313924; http://dx.doi.org/10.1038/sj.bjp.0701434

87. Loussouarn G, Charpentier F, Mohammad-Panah R, Kunzelmann K, Baró I, Escande D. KvLQT1 potassium channel but not IsK is the molecular target for trans-6-cyano-4-(N-ethylsulfonyl-N-methylamino)-3-hydroxy-2,2-dimethyl – chromane. Mol Pharmacol 1997; 52:1131-6; PMID:9396783

88. Wang HS, Brown BS, McKinnon D, Cohen IS. Molecular basis for differential sensitivity of KCNQ and I_{Ks} channels to the cognitive enhancer XE991. Mol Pharmacol 2000; 57:1218-23; PMID:10825393

89. Kang J, Chen XL, Wang L, Rampe D. Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG. J Pharmacol Exp Ther 2001; 299:290-6; PMID:11561091

90. Salata JJ, Jurkiewicz NK, Wang J, Evans BE, Orme HT, Sanguinetti MC. A novel benzodiazepine that activates cardiac slow delayed rectifier K⁺ currents. Mol Pharmacol 1998; 54:220-30; PMID:9658209

91. Yang WP, Levesque PC, Little WA, Conder ML, Shalaby FY, Blanar MA. KvLQT1, a voltage-gated potassium channel responsible for human cardiac arrhythmias. Proc Natl Acad Sci U S A 1997; 94:4017-21; PMID:9108097; http://dx.doi.org/10.1073/pnas.94.8.4017

92. Potet F, Scott JD, Mohammad-Panah R, Escande D, Baró I. AKAP proteins anchor cAMP-dependent protein kinase to KvLQT1/IsK channel complex. Am J Physiol Heart Circ Physiol 2001; 280:H2038-45; PMID:11299204

93. Loussouarn G, Demolombe S, Mohammad-Panah R, Escande D, Baró I. Expression of CFTR controls cAMP-dependent activation of epithelial K⁺ currents. Am J Physiol 1996; 271:C1565-73; PMID:8944640

94. Huang P, Trotter K, Boucher RC, Milgram SL, Stutts MJ. PKA holoenzyme is functionally coupled to CFTR by AKAPs. Am J Physiol Cell Physiol 2000; 278:C417-22; PMID:10666038

95. Warmke JW, Ganetzky B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci U S A 1994; 91:3438-42; PMID:8159766; http://dx.doi.org/10.1073/pnas.91.8.3438

96. Lastraioli E, Guasti L, Crociani O, Polvani S, Hofmann G, Witchel H, Bencini L, Calistri M, Messerini L, Scatizzi M, et al. herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells. Cancer Res 2004; 64:606-11; PMID:14744775; http://dx.doi.org/10.1158/0008-5472.CAN-03-2360

97. Saganich MJ, Vega-Saenz de Miera E, Nadal MS, Baker H, Coetzee WA, Rudy B. Cloning of components of a novel subthreshold-activating K⁺ channel with a unique pattern of expression in the cerebral cortex. J Neurosci 1999; 19:10789-802; PMID:10594062

98. Ju M, Wray D. Molecular identification and characterisation of the human eag2 potassium channel. FEBS Lett 2002; 524:204-10; PMID:12135768; http://dx.doi.org/10.1016/S0014-5793(02)03055-7

99. Huang X, Dubuc AM, Hashizume R, Berg J, He Y, Wang J, Chiang C, Cooper MK, Northcott PA, Taylor MD, et al. Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. Genes Dev 2012; 26:1780-96; PMID:22855790; http://dx.doi.org/10.1101/gad.193789.112

100. Gómez-Varela D, Zwick-Wallasch E, Knötgen H, Sánchez A, Hettmann T, Ossipov D, Weseloh R, Contreras-Jurado C, Rothe M, Stühmer W, et al. Monoclonal antibody blockade of the human Eag1 potassium channel function exerts antitumor activity. Cancer Res 2007; 67:7343-9; PMID:17671204; http://dx.doi.org/10.1158/0008-5472.CAN-07-0107

101. Pardo LA, Gómez-Varela D, Major F, Sansuk K, Leurs R, Downie BR, Tietze LF, Stühmer W. Approaches targeting K$_V$10.1 open a novel window for cancer diagnosis and therapy. Curr Med Chem 2012; 19:675-82; PMID:22204340; http://dx.doi.org/10.2174/092986712798992011

102. Kiehn J, Lacerda AE, Wible B, Brown AM. Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide. Circulation 1996; 94:2572-9; PMID:8921803; http://dx.doi.org/10.1161/01.CIR.94.10.2572

103. McDonald TV, Yu Z, Ming Z, Palma E, Meyers MB, Wang KW, Goldstein SA, Fishman GI. A minK-HERG complex regulates the cardiac potassium current I_{Kr}. Nature 1997; 388:289-92; PMID:9230439; http://dx.doi.org/10.1038/40882

104. Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, Keating MT, Goldstein SA. MiRP1 forms I_{Kr} potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999; 97:175-87; PMID:10219239; http://dx.doi.org/10.1016/S0092-8674(00)80728-X

105. Trudeau MC, Warmke JW, Ganetzky B, Robertson GA. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 1995; 269:92-5; PMID:7604285; http://dx.doi.org/10.1126/science.7604285

106. Korolkova YV, Kozlov SA, Lipkin AV, Pluzhnikov KA, Hadley JK, Filippov AK, Brown DA, Angelo K, Strøbæk D, Jespersen T, et al. An ERG channel inhibitor from the scorpion Buthus eupeus. J Biol Chem 2001; 276:9868-76; PMID:11136720; http://dx.doi.org/10.1074/jbc.M005973200

107. Restano-Cassulini R, Korolkova YV, Diochot S, Gurrola G, Guasti L, Possani LD, Lazdunski M, Grishin EV, Arcangeli A, Wanke E. Species diversity and peptide toxins blocking selectivity of ether-à-go-go-related gene subfamily K⁺ channels in the central nervous system. Mol Pharmacol 2006; 69:1673-83; PMID:16497878; http://dx.doi.org/10.1124/mol.105.019729

108. Gerlach AC, Stoehr SJ, Castle NA. Pharmacological removal of human ether-à-go-go-related gene potassium channel inactivation by 3-nitro-N-(4-phenoxyphenyl) benzamide (ICA-105574). Mol Pharmacol 2010; 77:58-68; PMID:19805508; http://dx.doi.org/10.1124/mol.109.059543

109. Abi-Gerges N, Holkham H, Jones EM, Pollard CE, Valentin JP, Robertson GA. hERG subunit composition determines differential drug sensitivity. Br J Pharmacol 2011; 164:419-32; PMID:21449979; http://dx.doi.org/10.1111/j.1476-5381.2011.01378.x

110. Qu Y, Fang M, Gao B, Chui RW, Vargas HM. BeKm-1, a peptide inhibitor of human ether-a-go-go-related gene potassium currents, prolongs QTc intervals in isolated rabbit heart. J Pharmacol Exp Ther 2011; 337:2-8; PMID:21205913; http://dx.doi.org/10.1124/jpet.110.176883

111. Gessner G, Heinemann SH. Inhibition of hEAG1 and hERG1 potassium channels by clofilium and its tertiary analogue LY97241. Br J Pharmacol 2003; 138:161-71; PMID:12522086; http://dx.doi.org/10.1038/sj.bjp.0705025

112. Suessbrich H, Schönherr R, Heinemann SH, Lang F, Busch AE. Specific block of cloned Herg channels by clofilium and its tertiary analog LY97241. FEBS Lett 1997; 414:435-8; PMID:9315735; http://dx.doi.org/10.1016/S0014-5793(97)01030-2

113. Gessner G, Zacharias M, Bechstedt S, Schönherr R, Heinemann SH. Molecular determinants for high-affinity block of human EAG potassium channels by antiarrhythmic agents. Mol Pharmacol 2004; 65:1120-9; PMID:15102940; http://dx.doi.org/10.1124/mol.65.5.1120

114. Zeng H, Lozinskaya IM, Lin Z, Willette RN, Brooks DP, Xu X. Mallotoxin is a novel human ether-a-go-go-related gene (hERG) potassium channel activator. J Pharmacol Exp Ther 2006; 319:957-62; PMID:16928897; http://dx.doi.org/10.1124/jpet.106.110593

115. Perry M, Sachse FB, Abbruzzese J, Sanguinetti MC. PD-118057 contacts the pore helix of hERG1 channels to attenuate inactivation and enhance K⁺ conductance. Proc Natl Acad Sci U S A 2009; 106:20075-80; PMID:19892732

116. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the I_{Kr} potassium channel. Cell 1995; 81:299-307; PMID:7736582; http://dx.doi.org/10.1016/0092-8674(95)90340-2

117. Kagan A, Melman YF, Krumerman A, McDonald TV. 14-3-3 amplifies and prolongs adrenergic stimulation of HERG K+ channel activity. EMBO J 2002; 21:1889-98; PMID:11953308; http://dx.doi.org/10.1093/emboj/21.8.1889

118. Li Y, Sroubek J, Krishnan Y, McDonald TV. A-kinase anchoring protein targeting of protein kinase A and regulation of HERG channels. J Membr Biol 2008; 223:107-16; PMID:18679741; http://dx.doi.org/10.1007/s00232-008-9118-4

119. Kiehn J, Karle C, Thomas D, Yao X, Brachmann J, Kübler W. HERG potassium channel activation is shifted by phorbol esters via protein kinase A-dependent pathways. J Biol Chem 1998; 273:25285-91; PMID:9737994; http://dx.doi.org/10.1074/jbc.273.39.25285

120. Thomas D, Zhang W, Karle CA, Kathöfer S, Schöls W, Kübler W, Kiehn J. Deletion of protein kinase A phosphorylation sites in the HERG potassium channel inhibits activation shift by protein kinase A. J Biol Chem 1999; 274:27457-62; PMID:10488078; http://dx.doi.org/10.1074/jbc.274.39.27457

121. Joiner WJ, Tang MD, Wang LY, Dworetzky SI, Boissard CG, Gan L, Gribkoff VK, Kaczmarek LK. Formation of intermediate-conductance calcium-activated potassium channels by interaction of Slack and Slo subunits. Nat Neurosci 1998; 1:462-9; PMID:10196543; http://dx.doi.org/10.1038/2176

122. Bhattacharjee A, Joiner WJ, Wu M, Yang Y, Sigworth FJ, Kaczmarek LK. Slick (Slo2.1), a rapidly-gating sodium-activated potassium channel inhibited by ATP. J Neurosci 2003; 23:11681-91; PMID:14684870

123. Yuan A, Santi CM, Wei A, Wang ZW, Pollak K, Nonet M, Kaczmarek L, Crowder CM, Salkoff L. The sodium-activated potassium channel is encoded by a member of the Slo gene family. Neuron 2003; 37:765-73; PMID:12628167; http://dx.doi.org/10.1016/S0896-6273(03)00096-5

124. Paulais M, Lachheb S, Teulon J. A Na+ – and Cl− – activated K+ channel in the thick ascending limb of mouse kidney. J Gen Physiol 2006; 127:205-15; PMID:16446508; http://dx.doi.org/10.1085/jgp.200509360

125. Yang B, Gribkoff VK, Pan J, Damagnez V, Dworetzky SI, Boissard CG, Bhattacharjee A, Yan Y, Sigworth FJ, Kaczmarek LK. Pharmacological activation and inhibition of Slack (Slo2.2) channels. Neuropharmacology 2006; 51:896-906; PMID:16876206; http://dx.doi.org/10.1016/j.neuropharm.2006.06.003

126. Biton B, Sethuramanujam S, Picchione KE, Bhattacharjee A, Khessibi N, Chesney F, Lanneau C, Curet O, Avenet P. The antipsychotic drug loxapine is an opener of the sodium-activated potassium channel slack (Slo2.2). J Pharmacol Exp Ther 2012; 340:706-15; PMID:22171093; http://dx.doi.org/10.1124/jpet.111.184622

127. Garg P, Sanguinetti MC. Structure-activity relationship of fenamates as Slo2.1 channel activators. Mol Pharmacol 2012; 82:795-802; PMID:22851714; http://dx.doi.org/10.1124/mol.112.079194

128. Berg AP, Sen N, Bayliss DA. TrpC3/C7 and Slo2.1 are molecular targets for metabotropic glutamate receptor signaling in rat striatal cholinergic interneurons. J Neurosci 2007; 27:8845-56; PMID:17699666; http://dx.doi.org/10.1523/JNEUROSCI.0551-07.2007

129. Dai L, Garg V, Sanguinetti MC. Activation of Slo2.1 channels by niflumic acid. J Gen Physiol 2010; 135:275-95; PMID:20176855; http://dx.doi.org/10.1085/jgp.200910316

130. Santi CM, Ferreira G, Yang B, Gazula VR, Butler A, Wei A, Kaczmarek LK, Salkoff L. Opposite regulation of Slick and Slack K+ channels by neuromodulators. J Neurosci 2006; 26:5059-68; PMID:16687497; http://dx.doi.org/10.1523/JNEUROSCI.3372-05.2006

131. Lesage F, Barhanin J. Molecular physiology of pH-sensitive background K_{2P} channels. Physiology (Bethesda) 2011; 26:424-37; PMID:22170960; http://dx.doi.org/10.1152/physiol.00029.2011

132. Duprat F, Girard C, Jarretou G, Lazdunski M. Pancreatic two P domain K+ channels TALK-1 and TALK-2 are activated by nitric oxide and reactive oxygen species. J Physiol 2005; 562:235-44; PMID:15513946; http://dx.doi.org/10.1113/jphysiol.2004.071266

133. Reyes R, Duprat F, Lesage F, Fink M, Salinas M, Farman N, Lazdunski M. Cloning and expression of a novel pH-sensitive two pore domain K+ channel from human kidney. J Biol Chem 1998; 273:30863-9; PMID:9812978; http://dx.doi.org/10.1074/jbc.273.47.30863

134. Medhurst AD, Rennie G, Chapman CG, Meadows H, Duckworth MD, Kelsell RE, Gloger II, Pangalos MN. Distribution analysis of human two pore domain potassium channels in tissues of the central nervous system and periphery. Brain Res Mol Brain Res 2001; 86:101-14; PMID:11165377; http://dx.doi.org/10.1016/S0169-328X(00)00263-1

135. Warth R, Barrière H, Meneton P, Bloch M, Thomas J, Tauc M, Heitzmann D, Romeo E, Verrey F, Mengual R, et al. Proximal renal tubular acidosis in TASK2 K+ channel-deficient mice reveals a mechanism for stabilizing bicarbonate transport. Proc Natl Acad Sci U S A 2004; 101:8215-20; PMID:15141089; http://dx.doi.org/10.1073/pnas.0400081101

136. Cotten JF, Zou HL, Liu C, Au JD, Yost CS. Identification of native rat cerebellar granule cell currents due to background K channel KCNK5 (TASK-2). Brain Res Mol Brain Res 2004; 128:112-20; PMID:15363886; http://dx.doi.org/10.1016/j.molbrainres.2004.06.007

137. La JH, Kang D, Park JY, Hong SG, Han J. A novel acid-sensitive K+ channel in rat dorsal root ganglia neurons. Neurosci Lett 2006; 406:244-9; PMID:16904821; http://dx.doi.org/10.1016/j.neulet.2006.07.039

138. Niemeyer MI, Cid LP, Barros LF, Sepúlveda FV. Modulation of the two-pore domain acid-sensitive K+ channel TASK-2 (KCNK5) by changes in cell volume. J Biol Chem 2001; 276:43166-74; PMID:11560934; http://dx.doi.org/10.1074/jbc.M107192200

139. Kindler CH, Paul M, Zou H, Liu C, Winegar BD, Gray AT, Yost CS. Amide local anesthetics potently inhibit the human tandem pore domain background K+ channel TASK-2 (KCNK5). J Pharmacol Exp Ther 2003; 306:84-92; PMID:12660311; http://dx.doi.org/10.1124/jpet.103.049809

140. Gray AT, Zhao BB, Kindler CH, Winegar BD, Mazurek MJ, Xu J, Chavez RA, Forsayeth JR, Yost CS. Volatile anesthetics activate the human tandem pore domain baseline K+ channel KCNK5. Anesthesiology 2000; 92:1722-30; PMID:10839924; http://dx.doi.org/10.1097/00000542-200006000-00032

141. Morton MJ, Abohamed A, Sivaprasadarao A, Hunter M. pH sensing in the two-pore domain K+ channel, TASK2. Proc Natl Acad Sci U S A 2005; 102:16102-6; PMID:16239344; http://dx.doi.org/10.1073/pnas.0506870102

142. Hayoz S, Bychkov R, Serir K, Docquier M, Bény JL. Purinergic activation of a leak potassium current in freshly dissociated myocytes from mouse thoracic aorta. Acta Physiol (Oxf) 2009; 195:247-58; PMID:18616685; http://dx.doi.org/10.1111/j.1748-1716.2008.01884.x

143. Nguyen TD, Meichle S, Kim US, Wong T, Moody MW. P2Y11, a purinergic receptor acting via cAMP, mediates secretion by pancreatic duct epithelial cells. Am J Physiol Gastrointest Liver Physiol 2001; 280:G795-804; PMID:11292586

144. Pedersen SF, Hoffmann EK, Novak I. Cell volume regulation in epithelial physiology and cancer. Front Physiol 2013; 4:233;

145. Prevarskaya N, Skryma R, Shuba Y. Ion channels and the hallmarks of cancer. Trends Mol Med 2010; 16:107-21; PMID:20167536; http://dx.doi.org/10.1016/j.molmed.2010.01.005

146. Brevet M, Fucks D, Chatelain D, Regimbeau JM, Delcenserie R, Sevestre H, Ouadid-Ahidouch H. Deregulation of 2 potassium channels in pancreas adenocarcinomas: implication of K_V1.3 gene promoter methylation. Pancreas 2009; 38:649-54; PMID:19465885; http://dx.doi.org/10.1097/MPA.0b013e3181a56ebf

147. Bielanska J, Hernández-Losa J, Pérez-Verdaguer M, Moline T, Somoza R, Ramón Y Cajal S, Condom E, Ferreres JC, Felipe A. Voltage-dependent potassium channels Kv1.3 and Kv1.5 in human cancer. Curr Cancer Drug Targets 2009; 9:904-14; PMID:20025600; http://dx.doi.org/10.2174/156800909790192400

148. Parks SK, Chiche J, Pouyssegur J. pH control mechanisms of tumor survival and growth. J Cell Physiol 2011; 226:299-308; PMID:20857482; http://dx.doi.org/10.1002/jcp.22400

149. Webb BA, Chimenti M, Jacobson MP, Barber DL. Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer 2011; 11:671-7; PMID:21833026; http://dx.doi.org/10.1038/nrc3110

150. Wilschanski M, Novak I. The cystic fibrosis of exocrine pancreas. In: Riordan JR, Boucher RC, Quinton PM, eds. Cystic Fibrosis: A Trilogy of Biochemistry, Physiology and Pathology. Cold Spring Harb Perspect Med 2013; 3(5):a009746; PMID:23637307; doi:10.1101/cshperspect.a009746.